ERBB2 T790M

CI-VAR-00004342Explore in graph →CIViC 4907

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
ERBB2 Activating Mutation OR ERBB2 T790M	Osimertinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID12026 In this phase 2 clinical trial, 19 patients with tumours harbouring EGFR mutations (T790M or activation mutations) were treated with osimertinib, an EGFR TKI. Of the 19 patients, 13 were evaluable for… (full text at CIViC) PMID 38591867 · Chen et al., 2024 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.